Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

142.82USD
22 Sep 2017
Change (% chg)

$-0.10 (-0.07%)
Prev Close
$142.92
Open
$142.43
Day's High
$143.21
Day's Low
$141.46
Volume
985,622
Avg. Vol
2,599,235
52-wk High
$149.34
52-wk Low
$96.18

Chart for

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $31,875.32
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

Sep 13 2017

BRIEF-Interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

Sep 13 2017

Alexion Pharma to lay off 20 percent of workforce

Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its workforce and sharpen its focus on its core rare disease drugs business, as it looks to restore investor confidence.

Sep 12 2017

UPDATE 2-Alexion Pharma to lay off 20 pct of workforce

* Drugmaker's shares down slightly (Adds details, analyst comment, updates share price)

Sep 12 2017

Drugmaker Alexion to cut 20 pct of jobs

Sept 12 U.S. drugmaker Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its global workforce in an effort to cut spending.

Sep 12 2017

BRIEF-Alexion to reduce 20 pct of its global workforce

* Alexion announces restructuring to advance corporate strategy

Sep 12 2017

BRIEF-Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027

* Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027

Aug 15 2017

BRIEF-Third Point LLC takes share stake in Blackrock Inc, Alexion Pharmaceuticals

* Third Point LLC takes share stake of 1.6 million shares in Blackrock Inc - SEC filing‍​

Aug 11 2017

Alexion posts higher second-quarter earnings on strong Soliris sales

NEW YORK Alexion Pharmaceuticals Inc posted a better than expected second-quarter profit on Thursday and raised its full-year forecast on strong sales of its expensive rare disease treatment Soliris.

Jul 27 2017

Alexion posts higher Q2 earnings on strong Soliris sales

NEW YORK, July 27 Alexion Pharmaceuticals Inc posted a better than expected second-quarter profit on Thursday and raised its full-year forecast on strong sales of its expensive rare disease treatment Soliris.

Jul 27 2017

Competitors

Earnings vs. Estimates